Q&A with Dr. Jena Miller: Charting New Frontiers in Fetal Medicine at CHOP
In January 2026, Dr. Jena Miller joined CHOP as Co-Director of the Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment. With over a decade at Johns Hopkins, she brings expertise in minimally invasive fetal procedures, spina bifida, and TTTS. Read her Q&A on advancing fetal medicine and supporting families.
Do you or your loved one qualify for a study evaluating an investigational medication for FNAIT?
The FREESIA-3 research study is investigating a new treatment for FNAIT, a rare condition that affects a baby’s platelet count during pregnancy. Pregnant women at risk may qualify for free study medication, care, and health evaluations for mother and baby. Learn more about this opportunity today!
The McGrew Family Story: When Your Baby Has FNAIT
3-minute read
Parents aren’t the only ones who may not be aware of the dire consequences of FNAIT. Many doctors and other medical professionals aren’t familiar with the blood disorder until there’s a serious problem. Raising awareness allows for better disease management and prevention. See how the McGrew family dealt with four FNAIT pregnancies.
What is FNAIT?
2-minute read
When a baby experiences FNAIT or NAIT it’s often not discovered until symptoms appear. That’s why it’s important to know the signs and understand if you and your pregnancy are at risk. The consequences of this condition that involves a low blood platelet count can be alleviated through awareness and prompt action.
What is HDFN?
2-minute read
HDFN is a rare fetal syndrome that affects later pregnancies. Johnson & Johnson is pioneering research to help women at severe risk. Their clinical trial is currently enrolling women who are at risk for severe HDFN who have a history of severe HDFN in a prior pregnancy.